EGFR-TKI Market - Global Forecast 2025-2030

The EGFR-TKI market is undergoing significant transformation as the demand for precision oncology solutions rises globally. Senior decision-makers are increasingly focused on therapies that offer targeted efficacy, improved patient outcomes, and supply chain resilience in a shifting regulatory and economic environment.

Market Snapshot: EGFR-TKI Market Size and Growth

The EGFR-TKI Market grew from USD 2.05 billion in 2024 to USD 2.22 billion in 2025. It is expected to continue growing at a CAGR of 8.52%, reaching USD 3.35 billion by 2030. This growth reflects the market’s response to evolving clinical needs and its pivotal role in advancing precision medicine. Accelerating innovation and expanding indications further reinforce EGFR-TKI’s strategic importance in targeted oncology therapies.

Scope & Segmentation

This report provides robust coverage and actionable segmentation of the EGFR-TKI market, with an emphasis on the following:

Generation: First Generation, Second Generation, Third Generation, Fourth Generation
Line of Therapy: Adjuvant Therapy, First Line Therapy, Maintenance Therapy, Second Line Therapy
Indication: Non-Small Cell Lung Cancer, Head & Neck Cancer
End User: Hospitals & Clinics, Specialty Centers
Geographies: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
Companies covered: Innovent Biologics, Johnson & Johnson Services, ArriVent BioPharma, ASSERTIO HOLDINGS, AstraZeneca, Betta Pharmaceuticals, Eli Lilly, F. Hoffmann-La Roche, Pfizer, Taiho Oncology, Takeda, Yuhan Corporation, Merck & Co.

The analysis addresses generational differences in inhibitors, sequential treatment strategies, a broadening indication landscape, and distinct usage trends among primary care sites and specialty centers.

Key Takeaways for Senior Decision-Makers

The EGFR-TKI sector is marked by rapid innovation, particularly with fourth generation inhibitors advancing in late-stage development to tackle resistance-related challenges and address unmet needs.
Molecular diagnostics and companion assays are increasingly central, enabling more precise patient selection and supporting adaptive dosing protocols.
Growth in adjuvant and maintenance therapies signals a broader clinical impact beyond initial treatment lines, with non-small cell lung cancer continuing to dominate clinical and commercial strategies.
Regional market performance varies significantly; the Americas benefit from strong R&D investments and robust reimbursement, while Asia-Pacific’s emphasis on biosimilar development and government-led programs expands reach.
Collaborative initiatives and value-based frameworks are emerging as critical tools to align drug acquisition costs with clinical outcomes and support payer engagement.

Tariff Impact: Navigating U.S. Trade Measures

The introduction of new United States tariff measures in 2025 has increased the complexity of supply chain management for EGFR-TKI stakeholders. Elevated import duties on essential components have intensified procurement and manufacturing costs, prompting a shift toward nearshoring and strategic partnerships. These adjustments are helping pharmaceutical companies safeguard supply continuity and mitigate pressure on margins, while payers and health systems recalibrate value-based contracting and reimbursement criteria. Localized production initiatives and collaborative approaches are likely to enhance future operational agility and manufacturing resilience across the ecosystem.

Methodology & Data Sources

This EGFR-TKI market analysis employs a rigorous approach, integrating primary interviews with senior executives in pharmaceutical, regulatory, and clinical domains, and secondary validation from peer-reviewed journals, clinical trial data, corporate filings, and patent records. Data triangulation and expert panel reviews underpin the reliability and depth of the report’s findings.

Why This Report Matters

Offers actionable intelligence for optimizing portfolio strategies and capitalizing on sector-specific therapeutic and technological advances.
Supports critical decision-making on global expansion, risk management, and new market entry amid changing regulations and value-based healthcare models.

Conclusion

The EGFR-TKI market is at the forefront of targeted oncology, with innovation, policy shifts, and clinical insight shaping future therapeutic paradigms. This report equips leaders with the knowledge needed for sustained growth, operational adaptation, and strategic advantage in a dynamic landscape.

This product will be delivered within 1-3 business days.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

5.1. Increasing need for EGFR-TKI due to rising incidence of non-small cell lung cancer
5.2. Adoption of EGFR-TKI due to superior targeted therapy over traditional chemotherapy
5.3. Rising demand for personalized medicine driving the use of EGFR mutation testing
5.4. Integration of liquid biopsy and next-generation sequencing in EGFR-TKI treatment decision making to personalize therapy
5.5. Technological advancements improving EGFR mutation detection and diagnostic accuracy
5.6. Growing awareness among physicians and patients regarding targeted therapies
5.7. Inclusion of EGFR-TKIs in clinical guidelines and reimbursement policies boosting adoption
5.8. Emergence of third-generation EGFR-TKIs addressing resistance to earlier therapies
5.9. Strategic collaborations and R&D investments by pharmaceutical companies fueling innovation
5.10. Expansion of healthcare infrastructure and oncology care in emerging markets

6. Market Insights

6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. EGFR-TKI Market, by Generation

8.1. Introduction
8.2. First Generation
8.3. Fourth Generation
8.4. Second Generation
8.5. Third Generation

9. EGFR-TKI Market, by Line Of Therapy

9.1. Introduction
9.2. Adjuvant Therapy
9.3. First Line Therapy
9.4. Maintenance Therapy
9.5. Second Line Therapy

10. EGFR-TKI Market, by Indication

10.1. Introduction
10.2. Head & Neck Cancer
10.3. Non-Small Cell Lung Cancer

11. EGFR-TKI Market, by End User

11.1. Introduction
11.2. Hospitals & Clinics
11.3. Specialty Centers

12. Americas EGFR-TKI Market

12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina

13. Europe, Middle East & Africa EGFR-TKI Market

13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland

14. Asia-Pacific EGFR-TKI Market

14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan

15. Competitive Landscape

15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Innovent Biologics
15.3.2. Johnson & Johnson Services, Inc.
15.3.3. ArriVent BioPharma
15.3.4. ASSERTIO HOLDINGS INC.
15.3.5. AstraZeneca PLC
15.3.6. Betta Pharmaceuticals Co., Ltd.
15.3.7. Eli Lilly and Company
15.3.8. F. Hoffmann-La Roche Ltd
15.3.9. Pfizer Inc.
15.3.10. Taiho Oncology, Inc.
15.3.11. Takeda Pharmaceutical Company Limited
15.3.12. Yuhan Corporation
15.3.13. Merck & Co., Inc.

16. ResearchAI17. ResearchStatistics18. ResearchContacts19. ResearchArticles20. Appendix

List of Figures

FIGURE 1. EGFR-TKI MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL EGFR-TKI MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL EGFR-TKI MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL EGFR-TKI MARKET SIZE, BY GENERATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL EGFR-TKI MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL EGFR-TKI MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL EGFR-TKI MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL EGFR-TKI MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL EGFR-TKI MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES EGFR-TKI MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES EGFR-TKI MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EGFR-TKI MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. EGFR-TKI MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. EGFR-TKI MARKET: RESEARCHAI
FIGURE 24. EGFR-TKI MARKET: RESEARCHSTATISTICS
FIGURE 25. EGFR-TKI MARKET: RESEARCHCONTACTS
FIGURE 26. EGFR-TKI MARKET: RESEARCHARTICLES

List of Tables

TABLE 1. EGFR-TKI MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL EGFR-TKI MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL EGFR-TKI MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL EGFR-TKI MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL EGFR-TKI MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL EGFR-TKI MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL EGFR-TKI MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL EGFR-TKI MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL EGFR-TKI MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL EGFR-TKI MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL EGFR-TKI MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL EGFR-TKI MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL EGFR-TKI MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL EGFR-TKI MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL EGFR-TKI MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL EGFR-TKI MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL EGFR-TKI MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL EGFR-TKI MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL EGFR-TKI MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL EGFR-TKI MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL EGFR-TKI MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL EGFR-TKI MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL EGFR-TKI MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL EGFR-TKI MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL EGFR-TKI MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL EGFR-TKI MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL EGFR-TKI MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL EGFR-TKI MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL EGFR-TKI MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL EGFR-TKI MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL EGFR-TKI MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS EGFR-TKI MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS EGFR-TKI MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 51. UNITED STATES EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 52. UNITED STATES EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES EGFR-TKI MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES EGFR-TKI MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 61. CANADA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 62. CANADA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 63. CANADA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 64. CANADA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 65. CANADA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. CANADA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. CANADA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. CANADA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. MEXICO EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 70. MEXICO EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 71. MEXICO EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 72. MEXICO EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 73. MEXICO EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. MEXICO EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. MEXICO EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. MEXICO EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. BRAZIL EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 78. BRAZIL EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. ARGENTINA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 86. ARGENTINA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 87. ARGENTINA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 88. ARGENTINA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA EGFR-TKI MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 106. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. GERMANY EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 112. GERMANY EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 113. GERMANY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 114. GERMANY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 115. GERMANY EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. GERMANY EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. GERMANY EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. GERMANY EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. FRANCE EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 120. FRANCE EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 121. FRANCE EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 122. FRANCE EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 123. FRANCE EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. FRANCE EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. FRANCE EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. FRANCE EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. RUSSIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 128. RUSSIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 129. RUSSIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 130. RUSSIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. ITALY EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 136. ITALY EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 137. ITALY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 138. ITALY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 139. ITALY EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. ITALY EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. ITALY EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. ITALY EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. SPAIN EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 144. SPAIN EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 145. SPAIN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 146. SPAIN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 147. SPAIN EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. SPAIN EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. SPAIN EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. SPAIN EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 160. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 162. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 168. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. DENMARK EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 176. DENMARK EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 177. DENMARK EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 178. DENMARK EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 179. DENMARK EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. DENMARK EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. DENMARK EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. DENMARK EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. NETHERLANDS EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 184. NETHERLANDS EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 185. NETHERLANDS EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 186. NETHERLANDS EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. QATAR EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 192. QATAR EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 193. QATAR EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 194. QATAR EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 195. QATAR EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. QATAR EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. QATAR EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. QATAR EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. FINLAND EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 200. FINLAND EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 201. FINLAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 202. FINLAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 203. FINLAND EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. FINLAND EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. FINLAND EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. FINLAND EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SWEDEN EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 208. SWEDEN EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 209. SWEDEN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 210. SWEDEN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. NIGERIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 216. NIGERIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 217. NIGERIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 218. NIGERIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. EGYPT EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 224. EGYPT EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 225. EGYPT EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 226. EGYPT EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 227. EGYPT EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. EGYPT EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. EGYPT EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EGYPT EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. TURKEY EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 232. TURKEY EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 233. TURKEY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 234. TURKEY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 235. TURKEY EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. TURKEY EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. TURKEY EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. TURKEY EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. ISRAEL EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 240. ISRAEL EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 241. ISRAEL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 242. ISRAEL EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. NORWAY EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 248. NORWAY EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 249. NORWAY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 250. NORWAY EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 251. NORWAY EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. NORWAY EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. NORWAY EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. NORWAY EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. POLAND EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 256. POLAND EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 257. POLAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 258. POLAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 259. POLAND EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. POLAND EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. POLAND EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. POLAND EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SWITZERLAND EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 264. SWITZERLAND EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 265. SWITZERLAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 266. SWITZERLAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 272. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC EGFR-TKI MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 281. CHINA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 282. CHINA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 283. CHINA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 284. CHINA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 285. CHINA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. CHINA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. CHINA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. CHINA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. INDIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 290. INDIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 291. INDIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 292. INDIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 293. INDIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. INDIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. INDIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. INDIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. JAPAN EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 298. JAPAN EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 299. JAPAN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 300. JAPAN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 301. JAPAN EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. JAPAN EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. JAPAN EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. JAPAN EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. AUSTRALIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 306. AUSTRALIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 307. AUSTRALIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 308. AUSTRALIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 309. AUSTRALIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. AUSTRALIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. AUSTRALIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. AUSTRALIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SOUTH KOREA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 314. SOUTH KOREA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH KOREA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 316. SOUTH KOREA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 317. SOUTH KOREA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. SOUTH KOREA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. SOUTH KOREA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. SOUTH KOREA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. INDONESIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 322. INDONESIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 323. INDONESIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 324. INDONESIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 325. INDONESIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. INDONESIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. INDONESIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. INDONESIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. THAILAND EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 330. THAILAND EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 331. THAILAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 332. THAILAND EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 333. THAILAND EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 334. THAILAND EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 335. THAILAND EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. THAILAND EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. PHILIPPINES EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 338. PHILIPPINES EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 339. PHILIPPINES EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 340. PHILIPPINES EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 341. PHILIPPINES EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. PHILIPPINES EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 343. PHILIPPINES EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 344. PHILIPPINES EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 345. MALAYSIA EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 346. MALAYSIA EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 347. MALAYSIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 348. MALAYSIA EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 349. MALAYSIA EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 350. MALAYSIA EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 351. MALAYSIA EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 352. MALAYSIA EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 353. SINGAPORE EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 354. SINGAPORE EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 355. SINGAPORE EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 356. SINGAPORE EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 357. SINGAPORE EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 358. SINGAPORE EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 359. SINGAPORE EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 360. SINGAPORE EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 361. VIETNAM EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 362. VIETNAM EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 363. VIETNAM EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 364. VIETNAM EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 365. VIETNAM EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 366. VIETNAM EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 367. VIETNAM EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 368. VIETNAM EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 369. TAIWAN EGFR-TKI MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
TABLE 370. TAIWAN EGFR-TKI MARKET SIZE, BY GENERATION, 2025-2030 (USD MILLION)
TABLE 371. TAIWAN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 372. TAIWAN EGFR-TKI MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 373. TAIWAN EGFR-TKI MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 374. TAIWAN EGFR-TKI MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 375. TAIWAN EGFR-TKI MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 376. TAIWAN EGFR-TKI MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 377. EGFR-TKI MARKET SHARE, BY KEY PLAYER, 2024
TABLE 378. EGFR-TKI MARKET, FPNV POSITIONING MATRIX, 2024

Samples

LOADING...

Companies Mentioned

The companies profiled in this EGFR-TKI Market report include:

Innovent Biologics
Johnson & Johnson Services, Inc.
ArriVent BioPharma
ASSERTIO HOLDINGS INC.
AstraZeneca PLC
Betta Pharmaceuticals Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Taiho Oncology, Inc.
Takeda Pharmaceutical Company Limited
Yuhan Corporation
Merck & Co., Inc.

Table Information

Report Attribute	Details
No. of Pages	182
Published	August 2025
Forecast Period	2025 - 2030
Estimated Market Value ( USD ) in 2025	$ 2.22 billion
Forecasted Market Value ( USD ) by 2030	$ 3.35 billion
Compound Annual Growth Rate	8.5%
Regions Covered	Global
No. of Companies Mentioned	14

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3144EUR$3,545USD£2,727GBP €3494EUR$3,939USD£3,030GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3392EUR$3,824USD£2,942GBP €3769EUR$4,249USD£3,269GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4597EUR$5,183USD£3,987GBP €5108EUR$5,759USD£4,430GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5563EUR$6,272USD£4,825GBP €6181EUR$6,969USD£5,361GBP

Market Snapshot: EGFR-TKI Market Size and Growth

Scope & Segmentation

Key Takeaways for Senior Decision-Makers

Tariff Impact: Navigating U.S. Trade Measures

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Samples

Companies Mentioned

Table Information

Related Reports

Pharmaceuticals - Enterprise ICT

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

Asia-Pacific Pharmaceutical Industry Outlook 2023

Anti-amyloid Therapy Market - Global Forecast 2025-2030

Rybrevant Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts